July 2026: The Medicare GLP-1 Bridge Goes Live, Foundayo Joins Medicare, and the Compounding Comment Window Closes
July 1 was the day Medicare's $50 GLP-1 Bridge finally turned on — Foundayo, all Wegovy formulations, and the Zepbound KwikPen now cost eligible beneficiaries a flat $50/month. Meanwhile the FDA's compounding comment period closed, Wegovy's $199 intro reset, and a most-favored-nation deal reset Medicare's list prices. Here's everything that changed for July.
For eighteen months, “Medicare will cover GLP-1s for weight loss” was a promise with a future date attached. As of July 1, 2026, it’s live. The Medicare GLP-1 Bridge — the demonstration CMS first previewed in the spring — turned on this week, and for the 67 million Americans on Medicare it changes the math on obesity treatment overnight. Here’s everything we updated across our 50+ provider profiles for July, plus what each change means for your choice of provider.
The Biggest Headlines
The Medicare GLP-1 Bridge Is Live — $50/Month, Nationwide
The headline event of the month, and arguably the year. On July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a temporary demonstration that lets eligible Medicare Part D beneficiaries fill covered GLP-1 weight-loss medications for a flat $50 monthly copay. The program runs through December 31, 2027.
What’s covered:
- All formulations of Foundayo (orforglipron)
- All formulations of Wegovy — both the injection and the oral tablet
- The KwikPen formulation of Zepbound (tirzepatide)
Who qualifies (clinical criteria):
- BMI of 35 or greater, or
- BMI of 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease, or
- BMI of 27+ with pre-diabetes, a prior heart attack, prior stroke, or symptomatic peripheral artery disease
A few details that surprised even us: the $50 is your total out-of-pocket cost — the Part D deductible doesn’t apply — but the copay does not count toward your TrOOP (true out-of-pocket) total, and there’s no low-income subsidy layered on top. Every fill requires prior authorization, and the drug must be prescribed for weight reduction and weight maintenance.
Because the mechanics here are genuinely complicated — how the claim adjudicates at the pharmacy counter, what prescribers have to document for the prior auth, which plans participate, and how the copay is reconciled — we published a complete deep-dive on how the Medicare GLP-1 Bridge works. If you’re on Medicare and trying to figure out whether you qualify and how to actually get a prescription filled, start there. You can also check eligibility directly at Medicare.gov/glp1bridge.
Foundayo Joins Medicare at $50 — The Cheapest Path Yet
The Foundayo (orforglipron) Medicare coverage that Lilly telegraphed back in the spring went live on schedule July 1 through the Bridge. Eligible Part D patients with prior authorization now pay $50/month for any Foundayo dose — the same as the injectables, but in a once-daily pill with no food, water, or timing restrictions.
For self-pay patients, Foundayo pricing is unchanged from the spring launch:
- 0.8 mg starter: $149/month
- 2.5 mg: $199/month
- 5.5–9 mg and 14.5–17.2 mg: $299/month (continuous refills)
Commercially insured patients with the Foundayo Savings Card can still pay as little as $25/month. Between the $50 Medicare copay, the $149 self-pay starter, and the $25 commercial card, Foundayo is now the lowest-cost FDA-approved GLP-1 in nearly every payer scenario — the tradeoff remaining its ~12.4% average weight loss versus ~21% for the top injectables. We’ve refreshed LillyDirect and LifeMD with current Foundayo pricing.
Wegovy’s $199 Intro Reset After June 30
Novo’s $199/month introductory offer on the Wegovy injection — the one we flagged as expiring — hit its June 30 sunset and was immediately restructured rather than killed outright. As of July:
- First two fills of 0.25 mg or 0.5 mg: $199/month (offer now extended through December 31, 2026)
- Standard maintenance doses (0.25–2.4 mg): $349/month
- Wegovy HD 7.2 mg: $399/month
- Wegovy oral 1.5 mg / 4 mg: $149/month (the 4 mg intro runs only through August 31, then $199)
Commercially insured patients can still drop to as little as $25/month with the Wegovy Savings Offer (capped at $100/month in savings). And of course, eligible Medicare patients now pay $50/month through the Bridge. We’ve updated Ro, NovoCare, LifeMD, GoodRx Care, and PlushCare to reflect the reset.
A Most-Favored-Nation Deal Resets Medicare List Prices
Running underneath the Bridge is a separate but related development: the manufacturers agreed to a most-favored-nation pricing deal that sets the Medicare price for injectable Ozempic, Mounjaro, Wegovy, and Zepbound at $245/month — across all doses and indications. This is the reference price that makes the $50 Bridge copay economically viable for CMS and plans, and it pulls the underlying “true” cost of these drugs down sharply from historical list prices north of $1,000.
For cash-pay shoppers outside Medicare, TrumpRx.gov verified its listings on July 1, with Zepbound listed around $346/month and Ozempic and Wegovy also live. The direct-to-consumer channel remains a fallback for patients who don’t qualify for the Bridge or a manufacturer intro offer.
FDA Compounding Comment Window Closed June 29
The other shoe the compounded market has been waiting on: the FDA’s public comment period on its proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list closed on June 29, 2026. The proposed rule — published in the Federal Register on May 1 — found “no clinical need” for outsourcing facilities to compound these drugs from bulk substances, citing 455+ adverse event reports for compounded semaglutide and 320+ for compounded tirzepatide.
The FDA now weighs the submitted comments before issuing a final determination. If finalized, the rule would shut down mass 503B compounding of these GLP-1s permanently, regardless of any future shortage. A narrower 503A patient-specific compounding path may survive, but the mass-marketed compounded model — the one that built much of the current telehealth GLP-1 industry — is on its last stretch of runway.
Our take: With Medicare now at $50, Foundayo self-pay at $149, and Wegovy’s intro at $199, the economic argument for compounded semaglutide keeps thinning even before the FDA rule finalizes. Every patient on compounded GLP-1s should have a branded backup plan mapped out now — not after a warning letter lands on their pharmacy.
Provider Landscape Changes
Novo’s Wegovy Subscription Expands Across Telehealth
Novo Nordisk’s co-branded Wegovy subscription — self-pay Wegovy delivered through telehealth partners — is now live across Ro, WeightWatchers Clinic, and LifeMD, with Hims and Sesame expected to join in the coming weeks. The structure standardizes self-pay Wegovy at $349/month (with the $199 two-fill intro) across every partner, so the differentiator between platforms is now clinical support and coaching rather than raw drug price.
LifeMD Goes Fully Branded
LifeMD confirmed it no longer offers compounded GLP-1s to new patients — the platform now routes everyone to branded medications through its Novo (Wegovy) and Lilly/LillyDirect (Zepbound, Foundayo) partnerships. It’s the most complete brand-name lineup in telehealth: Wegovy, Wegovy HD, Zepbound, and Foundayo all under one login. That completeness is why LifeMD keeps a top spot in our rankings.
Hims — SEC Investigation Still Open
Hims & Hers remains in the same holding pattern we flagged in the spring: the Novo lawsuit is settled and Hims is an authorized seller of branded Wegovy and Ozempic, but the SEC investigation into its prior compounded-GLP-1 disclosures is still open, and the HHS/DOJ referral remains pending. Hims is joining Novo’s Wegovy subscription, which further de-risks the branded side of the business — but until the SEC matter resolves, we’re keeping Hims out of our top rankings.
Pipeline Watch
Retatrutide — Still the One to Beat
Lilly’s triple agonist retatrutide continues to post the strongest efficacy in the class — 28.7% average weight loss (~71 lbs) at 68 weeks in TRIUMPH-4, plus meaningful osteoarthritis pain relief. The dysesthesia safety signal we flagged earlier (abnormal touch sensations, ~20.9% at the 12 mg dose vs. 0.7% on placebo) is still the thing to watch as the remaining 2026 Phase 3 readouts land. An approval is most likely in the 2027–2028 window.
CagriSema — Head-to-Head Data Lands
Novo’s CagriSema (cagrilintide + semaglutide) reported its REDEFINE 4 head-to-head against tirzepatide: ~20.2% body-weight reduction at 84 weeks, versus 23.6% for tirzepatide. Combined with REDEFINE 2’s 23% at 84 weeks (which missed its primary endpoint under the treatment-policy estimand), CagriSema looks like a strong-but-not-class-leading option. It keeps Novo competitive at the high-efficacy end while retatrutide reaches for the ceiling.
Updated Pricing Snapshot (July 2026)
| Option | Monthly Cost | Status |
|---|---|---|
| Medicare GLP-1 Bridge (Foundayo, Wegovy, Zepbound KwikPen) | $50/mo copay | LIVE since July 1 |
| Foundayo (orforglipron) | $149–299/mo self-pay; $25 w/ commercial card; $50 Medicare | Broadly available |
| Wegovy injection | $199 intro (first 2 fills) / $349 standard | Available |
| Wegovy HD 7.2mg | $399/mo | Available |
| Wegovy oral | $149/mo (4mg intro through Aug 31, then $199) | Available |
| Zepbound KwikPen | $50 Medicare / self-pay varies | Available |
| Medicare injectable reference price (MFN) | $245/mo | In effect |
| TrumpRx.gov (Zepbound) | ~$346/mo | Live, verified July 1 |
| Compounded semaglutide | $45–299/mo | Comment window closed June 29; final rule pending |
Rankings Impact
Our provider rankings reflect the July 2026 reality:
- Medicare-eligible patients now have a genuinely affordable branded path for the first time — if you’re 65+ and meet the clinical criteria, the Bridge deep-dive is the most important thing to read this month
- LifeMD stays a top pick as the most complete brand-name platform — Wegovy, Wegovy HD, Zepbound, and Foundayo under one roof, fully branded
- LillyDirect remains the cleanest manufacturer-direct option for Zepbound and Foundayo, with Medicare-friendly pricing
- Ro keeps a top recommendation for its clinical support and access to both the Wegovy subscription and Foundayo
- Hims stays out of our top rankings pending SEC resolution
- Compounded-only providers face a closing regulatory window — we flag this prominently on every profile
See our full Best GLP-1 Providers rankings, updated for July 2026.
Last updated: July 3, 2026. The GLP-1 market is moving fast — always verify pricing, coverage, and eligibility with your provider or plan before starting treatment. This article is educational and not medical advice.